Delving into the Latest Updates on Nebivolol hydrochloride with Synapse

This is a randomized, double-blind, crossover study in healthy adult subjects. Each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. All subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.

Start Date01 Jan 2030

Sponsor / Collaborator-

CTIS2025-521780-12-00

/ RecruitingPhase 4IIT

Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.

Start Date16 Dec 2025

Sponsor / Collaborator-

CTR20252570

/ CompletedNot Applicable

盐酸奈必洛尔片在健康受试者中的单次给药、随机、开放、两周期、双交叉、餐后状态下的生物等效性研究

[Translation] A single-dose, randomized, open-label, two-period, double-crossover, fed-state bioequivalence study of nebivolol hydrochloride tablets in healthy subjects

主要研究目的：以Menarini International Operations Luxembourg S.A.持证的盐酸奈必洛尔片（商品名：Nebilet）为参比制剂，以浙江花园药业有限公司持有的盐酸奈必洛尔片为受试制剂，通过单中心、随机、开放、单次给药、两周期、双交叉临床研究来评价两种制剂的人体生物等效性。次要研究目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

The main purpose of the study is to use the nebivolol hydrochloride tablets (trade name: Nebilet) licensed by Menarini International Operations Luxembourg S.A. as the reference preparation and the nebivolol hydrochloride tablets held by Zhejiang Huayuan Pharmaceutical Co., Ltd. as the test preparation to evaluate the human bioequivalence of the two preparations through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date21 Jul 2025

Sponsor / Collaborator

Zhejiang Garden Pharmaceutical Co., Ltd.

100 Clinical Results associated with Nebivolol hydrochloride

Login to view more data

100 Translational Medicine associated with Nebivolol hydrochloride

Login to view more data

100 Patents (Medical) associated with Nebivolol hydrochloride

Login to view more data

942

Literatures (Medical) associated with Nebivolol hydrochloride

01 May 2026·TALANTA

Capillary blood microsampling and LC–Orbitrap analysis for adherence monitoring of cardiovascular drugs: method development, cross-validation, and patient proof-of-concept using VAMS and Capitainer-B

Article

Author: Meyer, Markus R ; Böhm, Michael ; Wagmann, Lea ; Mahfoud, Felix ; Markwirth, Philipp ; Kretschmer, Diana ; Tokcan, Mert

Microsampling enables decentralized adherence monitoring by capturing defined volumes of capillary blood. We developed, validated, and cross-evaluated a volumetric absorptive microsampling (VAMS) and Capitainer-B workflow for 15 cardiovascular drugs using high-resolution liquid chromatography Orbitrap analysis. Amlodipine, atenolol, atorvastatin, bisoprolol, carvedilol, clopidogrel, diltiazem, lercanidipine, metoprolol, nebivolol, prasugrel, rosuvastatin, salicylic acid, simvastatin hydroxy acid, and verapamil were included. Sampling by VAMS and Capitainer-B should be evaluated and compared. VAMS tips and Capitainer-B disks loaded with 10 μL whole blood were extracted with 200 μL methanol, shaken and centrifuged, evaporated to dryness, reconstituted, and injected for analysis. The method met international validation criteria for most analytes, with quantification and selectivity achieved for all except prasugrel. Capitainer-B generally exhibited higher matrix effects than VAMS, while accuracy and precision were within acceptance limits except for lercanidipine across both devices and for atorvastatin on Capitainer-B. Under long-term storage, VAMS showed >15 % loss for carvedilol, lercanidipine, and simvastatin hydroxy acid after two weeks, whereas Capitainer-B showed no degradation. In a proof-of-concept involving 30 patients, finger-prick concentrations from VAMS and Capitainer-B were interchangeable, supporting the suitability of these adherence workflows but reference ranges for capillary blood remain necessary to enable routine clinical interpretation. In summary, this work established a reliable, LC-Orbitrap-based microsampling platform for monitoring adherence and identified stability issued amongst others that guide future method selection and development.

01 Mar 2026·VASCULAR PHARMACOLOGY

Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes

Review

Author: Ginghina, Edoardo Roberto ; Frati, Giacomo ; Biondi-Zoccai, Giuseppe ; Vitali, Andrea ; Di Napoli, Lucia Fatima

Heart failure (HF) remains a major global health challenge, marked by clinical heterogeneity and high morbidity, especially among elderly and comorbid patients. While β-blockers are central to HF management, conventional agents often present tolerability limitations, particularly in populations with preserved ejection fraction (HFpEF) or impaired vascular function. Nebivolol, a third-generation β-blocker characterized by high β₁-selectivity and nitric oxide-mediated vasodilation, offers a differentiated therapeutic profile with potential advantages in these subgroups. This review synthesizes current evidence on nebivolol's pharmacologic mechanisms, including its dual action on adrenergic and endothelial pathways, as well as its antioxidant and anti-inflammatory effects. Preclinical studies and translational biomarkers support their vascular and myocardial protective actions, while the SENIORS trial provides pivotal clinical evidence demonstrating efficacy across ejection fraction spectrums in elderly HF patients. Comparative data further reinforces its tolerability and favorable metabolic impact relative to traditional β-blockers. Nebivolol's role is also explored in guideline contexts and its potential utility in special populations such as those with renal impairment, diabetes, or cancer therapy-related cardiac dysfunction. Looking ahead, advances in pharmacogenomics, digital phenotyping, and adaptive trial designs may help personalize nebivolol therapy. This review underscores nebivolol's emerging position in the evolving landscape of HF treatment.

03 Feb 2026·Journal of the American Heart Association

Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study

Article

Author: Ho, Wan‐Jing ; Chang, Yu‐Cheng ; Lee, Kuang‐Tso ; Chu, Pao‐Hsien ; Ling, Ann Wan‐Chin

Background:

Beta blockers represent an important class of antihypertensive agents, but comparative data on different beta blockers in the treatment of hypertension remain limited. Nebivolol, a third‐generation beta blocker, possesses unique pharmacological properties. This study aimed to evaluate its real‐world effectiveness in blood pressure and heart rate control, as well as the associated clinical outcomes in patients with hypertension.

Methods:

We conducted a retrospective review of the Chang Gung Research Database to identify patients with hypertension who were newly prescribed beta blockers—primarily nebivolol, carvedilol, and bisoprolol—between 2018 and 2023. Inverse probability of treatment weighting was applied to balance the baseline characteristics across groups. Outcomes included changes in blood pressure and heart rate, as well as the incidence of major adverse cardiovascular events.

Results:

We identified 99 942 patients with hypertension. After inverse probability of treatment weighting, the patients treated with nebivolol had significantly greater reductions in systolic blood pressure (−11.0 mm Hg [95% CI, −11.6 to −10.4]), diastolic blood pressure (−8.1 mm Hg [95% CI, −8.5 to −7.6]), and heart rate (−7.3 bpm [95% CI, −7.8 to −6.9]) compared with carvedilol and other beta blockers. During a mean follow‐up of 4.5 years, nebivolol use was associated with a significantly lower risk of all‐cause mortality (hazard ratio [HR], 0.73 [95% CI, 0.63–0.86]) and major adverse cardiovascular events (HR, 0.81 [95% CI, 0.74–0.90]).

Conclusions:

In this retrospective cohort study of patients with hypertension without heart failure, nebivolol was associated with greater reductions in blood pressure and heart rate, as well as a lower risk of all‐cause mortality and major adverse cardiovascular events, compared with carvedilol and other beta blockers. Although these findings suggest potential benefits of nebivolol in this population, prospective studies are needed to validate these observations.

9

News (Medical) associated with Nebivolol hydrochloride

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

14 Apr 2025

·www.fiercepharma.com

Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant

The North Carolina facility cited in the FDA's Form 483 produces inhalers and dermatology products. Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA.Aurobindo's subsidiary Aurolife Pharma received a Form 483 from the FDA outlining 11 observations at a U.S. production plant, the Indian drugmaker said in a filing late last week. The exact nature of the infractions remain unclear, as the FDA has not published the document.The regulatory rebuke follows an inspection at Aurolife's Raleigh, North Carolina, manufacturing facility that ran from March 24 through April 10, Aurobindo explained in a filing (PDF) Friday with the National Stock Exchange of India and BSE, formerly known as the Bombay Stock Exchange. The facility produces inhalers and dermatology products.In its filing, the company characterized the regulator's observations as “procedural in nature” and said that it will promptly submit a response to the FDA detailing corrective measures at the plant. “We do not expect this development to have any material impact on the current business operations or existing supplies from this facility,” Aurobindo said. Aurobindo is no stranger to FDA scrutiny. In late 2024, the company recalled more than 103,000 bottles of cinacalcet tablets thanks to unacceptable levels of the potential carcinogen N-nitroso Cinacalcet. The drug is used to treat hyperparathyroidism in patients with chronic kidney disease who are on dialysis.At the same time, the company also recalled an undisclosed amount of the high blood pressure drug nebivolol, also due to the presence of excess levels of a nitrosamine drug substance-related impurity. Meanwhile, last August, the FDA slammed Aurobindo’s Eugia manufacturing unit near Hyderabad, India, with a warning letter after the site had received an official action indicated (OAI) notice in May. An OAI designation is a sort of precursor to more formal reprimands from the FDA indicating that a facility risks running afoul of regulatory and administrative requirements and could pose a danger to public health.At the time of its warning letter in August, Eugia had been cited with four Form 483s at various facilities throughout India since late 2023. In December 2023, the FDA also issued a citation for a plant in New Jersey that Aurobindo said it planned to sell.

NDA

18 Dec 2024

·www.fiercepharma.com

Trio of Indian drugmakers issue recalls tied to impurity, labeling issues

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate drug recalls linked to issues with impurities and labeling. Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling.The product pulls were reported in a recent edition of the U.S. FDA's weekly enforcement report, which catalogs recalls after they've been properly classified by the regulator.In the case of Aurobindo, the company issued a recall of more than 100,000 bottles of cinacalcet at the 30 mg dose and more than 3,300 bottles at the 60 mg dose. The company also recalled an undisclosed number of 90 mg bottles.The drug is used to treat hyperparathyroidism in patients with chronic kidney disease who are on dialysis.The recall for cinacalcet, which was manufactured in India, was attributed to the presence of N-nitroso Cinacalcet impurity levels that exceeded recommended limits set by the FDA. N-nitroso compounds are considered potentially carcinogenic. The drugs in question were distributed nationwide in the U.S., and the recall has been classified as Class II, which means there is a low chance of serious injuries or death. Aurobindo also recalled an undisclosed amount of nebivolol 2.5 mg tablets in 30-count bottles due to the presence of excess levels of the nitrosamine drug substance-related impurity N-Nitroso Nebivolol. The recall of nebivolol, which is used to treat high blood pressure, is also classified as Class II. The tablets were shipped out across the U.S., though Aurobindo didn’t specify where the products were manufactured.Glenmark Pharmaceuticals, for its part, issued voluntary recalls for 90,528 bottles of the high blood pressure drug diltiazem hydrochloride in tablet and extended-release forms due to unacceptable levels of another N-nitroso compound, N-nitroso-Desmethyl-Diltiazem. The suspect diltiazem lots were manufactured by Glenmark in India for multiple different customers. As with the other recalls listed in the enforcement report, Glenmark’s medicine withdrawal falls under Class II.Meanwhile, Zydus Pharmaceuticals recalled 4,404 40 mg single-dose packets of the acid reflux treatment esomeprazole magnesium due to a labeling issue. The product, which was produced in India, was distributed nationwide in the U.S. The recall has been classified as Class III, which is the least severe of the FDA’s recall rankings. N-nitroso compounds, and in particular nitrosamines, crop up in countless products, including cured meats, beer and medicine. Some nitrosamines cause cancer in laboratory animals and may increase the risk of certain types of cancer in humans, according to the National Cancer Institute. Notably, the discovery of N-nitrosodimethylamine (NDMA) in Zantac led to mass product pulls and lawsuits over the popular heartburn med around the start of the decade. More recently, Dr. Reddy’s Laboratories in November said it was yanking 331,590 bottles of cinacalcet—the same drug covered in Aurobindo's recall—after uncovering traces of a nitrosamine-related impurity in certain batches of the product.

100 Deals associated with Nebivolol hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06622	Nebivolol hydrochloride	C07AB12	DB04861

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Allergan Sales LLC	17 Dec 2007
Chronic heart failure	Austria	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	Greece	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	Ireland	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	Italy	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	Netherlands	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	Spain	Menarini International Operations Luxembourg SA	04 Apr 1996
Chronic heart failure	United Kingdom	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Austria	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Greece	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Ireland	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Italy	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Netherlands	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	Spain	Menarini International Operations Luxembourg SA	04 Apr 1996
Essential Hypertension	United Kingdom	Menarini International Operations Luxembourg SA	04 Apr 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 3	United States	Forest Laboratories LLC	01 Jan 2012
Diabetes Mellitus, Type 2	Phase 3	United States	Forest Laboratories LLC	01 Jan 2009
Heart Failure	Phase 3	United States	Forest Laboratories LLC	01 Jan 2009
Stiffness	Phase 3	United States	Forest Laboratories LLC	01 Jan 2009
Arterial Occlusive Diseases	Phase 3	Germany	BERLIN-CHEMIE AG	29 Mar 2006
Peripheral Arterial Disease	Phase 3	Germany	BERLIN-CHEMIE AG	29 Mar 2006
Tachycardia	Phase 3	Germany	Berlin-Chemie/Menarini Pharma GmbH	12 Sep 2005
Ventricular Dysfunction, Left	Phase 3	Romania	Berlin-Chemie/Menarini Pharma GmbH	01 Apr 2005
Fatty Liver	Phase 1	United States	Forest Laboratories LLC	01 Apr 2011
Multiple System Atrophy	Clinical	United States	Forest Laboratories LLC	01 Jan 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05328310 (Pubmed \| Am J Hypertens)	Not Applicable	Hypertension	98	Nebivolol	togvwvssky(qsnpcqvecy): Difference = 12.7 (95.0% CI, 4.1 - 21.2), P-Value = 0.004 View more	Negative	01 Feb 2026
				Telmisartan
NCT05170061 (ACRPP, CTgov)	Phase 3	Hypertension	26	Nebivolol (Nebivolol)	ngqwyfdvfh(rooplwnxwz) = xilvoanwhh dbleppnunn (bjfutnhfqo, 400) View more	-	08 Jun 2025
				Valsartan (Valsartan)	ngqwyfdvfh(rooplwnxwz) = zybljyhmoc dbleppnunn (bjfutnhfqo, 530) View more
NCT06104423 (ARTEMISIA, CTgov)	Phase 4	Hypertension	266	Nebivolol 5 mg+Ramipril 2.5/5/10 mg	nsvtekdntu(vekoezrtqd) = uwzcfvdzew gxltmlsgqv (befixisshs, lmosdydrfv - fecqethvnn) View more	-	24 Apr 2025
NCT04130438 (CTgov)	Phase 2	Angina Pectoris \| Myocardial Bridging \| Angina, Stable	5	Nebivolol (Beta Blocker (Nebivolol))	xphiyrodba(vbffbqxhcn) = qtfgjwhmfz jijahiopvl (fvlqosqypx, 24.4) View more	-	25 Feb 2025
				Diltiazem (Calcium Channel Blocker (Diltiazem))	xphiyrodba(vbffbqxhcn) = lkyjunzmbv jijahiopvl (fvlqosqypx, NA) View more
NCT05513937 (Botticelli, CTgov)	Phase 4	Hypertension	301	Nebivolol+Amlodipine (Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg)	aejqjlyfhb(orfbyjrmqw) = mmlmhxusah mwtalksozu (lwwraiicgp, 8.32)	-	04 Feb 2025
				Nebivolo (Nebivolo 5 mg MONOTHERAPY PERIOD)	dkzimhydoe(kclzeuzpxo) = chxurclaty zjjgmdrekx (cgimhrumff, ldwtyuyinz - pykehtxkar) View more
NCT05257148 (Masaccio, CTgov)	Phase 4	Hypertension	283	Nebivolol+Zofenopril (COMBINATION THERAPY PERIOD Zofenopril 30mg/Nebivolol 5mg)	lauqliodyd(yvzxpwmhur) = xmgerbpxxa jjnwzmzfqp (tygbkjzfut, 8.94)	-	20 Sep 2024
				Zofenopril (Zofenopril 30mg MONOTHERAPYPERIOD)	ttjuhpbpml(nhzqzzcyjh) = aoeypepgji vojoopcocd (sdwutrazdq, rnkeaqfnbz - lmowldfiup) View more
ESC 12022 \| ESC 22022 Manual	Not Applicable	Hypertension	98	nebivolol	jpaizxmows(qbtyzzhrgs) = bwjgojjcyb kapldbyurb (ukyoddjhgr, 3) View more	Positive	28 Aug 2022
				Telmisartan	jpaizxmows(qbtyzzhrgs) = xqpwpkyweg kapldbyurb (ukyoddjhgr, 3) View more
NCT00142584 (CTgov)	Phase 3	Hypertension	336	Nebivolol+NEB (1-NEB)	mwhearloax(etmmzqeeqk) = xettsrfvzj ouodfthwrh (lwhmwotref, 9.80) View more	-	15 Mar 2022
				Metoprolol (MET) (2-MET)	mwhearloax(etmmzqeeqk) = euvcookyve ouodfthwrh (lwhmwotref, 8.73) View more
NCT02053246 (CTgov)	Phase 4	Heart failure with normal ejection fraction \| Hypertension, Pulmonary \| Heart Failure, Diastolic	11	Nebivolol	xzbzaignjq(syipulhcvm) = yrpiwzazqe mnufikregk (rlibynrbwf, 6.32) View more	-	10 Feb 2022
NCT02710071 (nebhctz, CTgov)	Phase 4	Sleep Apnea, Obstructive \| Hypertension	41	Placebo (Placebo)	eqxpfqpqwk(uoasknwule) = ltctobfgql rvntnsnaqx (yohpgswcaw, 3.1) View more	-	19 Oct 2020
				Nebivolol (Nebivolol)	eqxpfqpqwk(uoasknwule) = ljtqxqmmty rvntnsnaqx (yohpgswcaw, 2.5) View more